Comparison of Clinical Efficacy and Safety between 70–150 µm and 100–300 µm Doxorubicin Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma

Background: This study aimed to compare the efficacy and safety of 70–150 μm doxorubicin drug-eluting bead (DEB) transarterial chemoembolization (TACE) with those of 100–300 μm DEB-TACE as first-line treatment in patients with hepatocellular carcinoma (HCC). Methods: We retrospectively investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Jung Woo, Hong, Hyun Pyo, Kim, Myung Sub, Shin, Byung Seok, Kwon, Heon-Ju, Kim, Byung Ik, Sohn, Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877410/
https://www.ncbi.nlm.nih.gov/pubmed/35207584
http://dx.doi.org/10.3390/life12020297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877410/
https://www.ncbi.nlm.nih.gov/pubmed/35207584
http://dx.doi.org/10.3390/life12020297

Ejemplares similares